https://orcid.org/0000-0001-7891-7706
References
- Younossi Z, Henry L. Contribution of alcoholic and nonalcoholic fatty liver disease to the burden of liver-related morbidity and mortality. Gastroenterology. 2016;150(8):1778–1785.
- Tsochatzis EA, Newsome PN. Non-alcoholic fatty liver disease and the interface between primary and secondary care. Lancet Gastroenterol Hepatol. 2018;3(7):509–517.
- Karlsen TH, Sheron N, Zelber-Sagi S, et al. The EASL-Lancet liver commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet. 2022;399(10319):61–116.
- Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547–1554.
- Lackner C, Spindelboeck W, Haybaeck J, et al. Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease. J Hepatol. 2017;66(3):610–618.
- Rehm J, Taylor B, Mohapatra S, et al. Alcohol as a risk factor for liver cirrhosis: a systematic review and meta-analysis. Comparative study multicenter study research support, N.I.H., extramural research support, non-U.S. Gov’t review. Drug Alcohol Rev. 2010;29(4):437–445.
- Srivastava A, Gailer R, Tanwar S, et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. J Hepatol. 2019;71(2):371–378.
- Rhodes FA, Cococcia S, Patel P, et al. Is there scope to improve the selection of patients with alcohol-related liver disease for referral to secondary care? A retrospective analysis of primary care referrals to a UK liver centre, incorporating simple blood tests. BMJ Open. 2021;11(6):e047786.
- Elangovan H, Rajagopaul S, Williams SM, et al. Nonalcoholic fatty liver disease: interface between primary care and hepatology clinics. Hepatol Commun. 2020;4(4):518–526.
- Patel PJ, Banh X, Horsfall LU, et al. Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis. Intern Med J. 2018;48(2):144–151.
- Blais P, Husain N, Kramer JR, et al. Nonalcoholic fatty liver disease is underrecognized in the primary care setting. Am J Gastroenterol. 2015;110(1):10–14.
- Lindvig KP, Hansen TL, Madsen BS, et al. Diagnostic accuracy of routine liver function tests to identify patients with significant and advanced alcohol-related liver fibrosis. Scand J Gastroenterol. 2021;56(9):1088–1095.
- Harris R, Harman DJ, Card TR, et al. Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review. Lancet Gastroenterol Hepatol. 2017;2(4):288–297.
- Chalmers J, Wilkes E, Harris R, et al. The development and implementation of a commissioned pathway for the identification and stratification of liver disease in the community. Frontline Gastroenterol. 2020;11(2):86–92.
- Papatheodoridi M, Hiriart JB, Lupsor-Platon M, et al. Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease. J Hepatol. 2021;74(5):1109–1116.
- Clark VC, Marek G, Liu C, et al. Clinical and histologic features of adults with alpha-1 antitrypsin deficiency in a non-cirrhotic cohort. J Hepatol. 2018;69(6):1357–1364.
- EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406–460.
- Newsome PN, Cramb R, Davison SM, et al. Guidelines on the management of abnormal liver blood tests. Gut. 2018;67(1):6–19.
- Armstrong MJ, Marchesini G. Referral pathways for NAFLD fibrosis in primary care - No longer a 'needle in a haystack. J Hepatol. 2019;71(2):246–248.
- Colwill M, Songra L, Yalçın M, et al. Transient elastography is underutilised in London hospitals and results in unnecessary endoscopic screening for oesophageal varices: a multi-site audit of practice. Gut. 2020;69. DOI:10.1136/gutjnl-2020-BASL.27